Supplementary Table 6. Certainty of evidence assessment with GRADE approach

| Participants (studies) | Certainty assessment | | | | | | Summary of findings |
	Risk of bias	Inconsistency	Indirectness	Imprecision	Other consideration	Certainty of evidence	Impact
eGFR slope							
28,038 (6 obs. studies)	Not serious	Not serious	Not serious	Not serious	None	⊕⊕○○ Low	MD, 0.64; 95% CI: 0.437–0.843; $P<0.01$
Major adverse kidney events							
15,610 (3 obs. studies)	Not serious	Not serious	Not serious	Not serious	None	⊕⊕○○ Low	HR, 1.01; 95% CI: 0.869–1.173; $P=0.87$
Hospitalized heart failure and cardiovascular death							
3,841 (2 obs. studies)	Not serious	Not serious	Not serious	Serious[a]	None	⊕○○○ Very low	HR, 0.824; 95% CI: 0.633–1.074; $P=0.10$
Hospitalized heart failure							
12,030 (2 obs. studies)	Not serious	Not serious	Not serious	Very serious[b]	None	⊕○○○ Very low	HR, 1.059; 95% CI: 0.574–1.952; $P=0.79$
All-cause mortality							
3,857 (2 obs. studies)	Not serious	Not serious	Not serious	Serious[a]	None	⊕○○○ Very low	HR, 0.83; 95% CI: 0.589–1.170; $P=0.18$
Discontinuation of SLGT2i due to adverse events							
11,826 (4 obs. studies)	Not serious	Not serious	Not serious	Not serious	None	⊕⊕○○ Low	OR, 1.023; 95% CI: 0.832–1.257; $P=0.4$
Serious adverse events							
9,518 (3 obs. studies)	Not serious	Not serious	Not serious	Not serious	None	⊕⊕○○ Low	OR, 0.991; 95% CI: 0.918–1.070; $P=0.87$
Kidney-related adverse events							
11,826 (4 obs. studies)	Not serious	Not serious	Not serious	Serious[c]	None	⊕○○○ Very low	OR, 1.216; 95% CI: 0.873–1.695; $P=0.21$
Acute kidney injury							
9,222 (3 obs. studies)	Not serious	Not serious	Not serious	Very serious[b]	None	⊕○○○ Very low	OR, 0.949; 95% CI: 0.510–1.767; $P=0.84$
Volume depletion							
4,383 (2 obs. studies)	Not serious	Not serious	Not serious	Serious[c]	None	⊕○○○ Very low	OR, 1.190; 95% CI: 0.869–1.630; $P=0.18$
Hyperkalemia							
7,443 (2 obs. studies)	Not serious	Not serious	Not serious	Serious[c]	None	⊕○○○ Very low	OR, 1.144; 95% CI: 0.954–1.371; $P=0.10$

GRADE, Grading of Recommendations Assessment, Development and Evaluation; eGFR, estimated glomerular filtration rate; obs., observational; MD, mean difference; CI, confidence interval; HR, hazard ratio; SGLT2i, sodium-glucose cotransporter-2 inhibitor; OR, odds ratio.
[a]The confidence interval includes no difference and potential benefit, [b]The confidence interval includes potential benefit and harm, [c]The confidence interval includes no difference and potential harm.